Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?

Neuroendocrinology
Elettra MerolaAlia Munir

Abstract

The correct histopathological diagnosis of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) is crucial for treatment selection and prognostication. It is also very challenging due to limited experience in nonexpert centers. Revision of pathology is standard of care for most patients who are referred to NEN expert centers. To describe the clinical impact of histopathological revision for GEP-NEN patients referred to an expert center. Retrospective multicenter analysis of all GEP-NENs receiving a histopathological revision in 6 European NEN expert centers (January 2016 to December 2016) to evaluate the impact on patient management. 175 patients were included and 14.7% referred for a second opinion. Histological samples were 69.1% biopsies, 23.4% surgical specimens, and 7.5% endoscopic resections. Histopathological changes due to revision included first assessment of Ki67 in 8.6% of cases, change in grading in 11.4% (3.4% G1 to G2; 5.7% G2 to G1; 0.6% G2 to G3; 1.7% G3 to G2), definition of tumor invasion in 10.8%, additional immunohistochemical staining in 2.3%, diagnosis of mixed adenoneuroendocrine carcinoma in 3.4%, exclusion of NEN in 3.4%, first diagnosis of NEN in 2.3%, and tumor differentiation for G3 in 1.7%. Th...Continue Reading

References

Jan 12, 2005·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·Z Z R HamadyK A Maclennan
Sep 13, 2006·Virchows Archiv : an International Journal of Pathology·G RindiUNKNOWN European Neuroendocrine Tumor Society (ENETS)
Aug 4, 2007·Virchows Archiv : an International Journal of Pathology·G RindiB Wiedenmann
Feb 28, 2008·The American Journal of Surgical Pathology·Anja M SchmittAurel Perren
Aug 29, 2009·Neuroendocrinology·Rudolf ArnoldUNKNOWN European Neuroendocrine Tumor Society
Jan 22, 2010·The Journal of Urology·Michael C LeeJ Stephen Jones
Jun 27, 2015·Endocrine-related Cancer·M HeetfeldUNKNOWN other Knowledge Network members
Jan 6, 2016·Neuroendocrinology·U-F PapeUNKNOWN Vienna Consensus Conference participants
Jan 6, 2016·Neuroendocrinology·J K RamageUNKNOWN Vienna Consensus Conference participants
Jan 6, 2016·Neuroendocrinology·R Garcia-CarboneroUNKNOWN Vienna Consensus Conference participants
Jan 14, 2016·Neuroendocrinology·B NiederleUNKNOWN Vienna Consensus Conference participants
Jan 20, 2016·Neuroendocrinology·G Delle FaveUNKNOWN Vienna Consensus Conference participants
Dec 7, 2016·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Friederike GrevenkampStefan Kommoss
Feb 25, 2017·The Oncologist·Francesco PanzutoGianfranco Delle Fave
May 2, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Camille LaurentPhilippe Gaulard
May 13, 2017·The American Journal of Surgical Pathology·Zhaohai YangLaura H Tang
Nov 15, 2017·Virchows Archiv : an International Journal of Pathology·Günter Klöppel, Stefano La Rosa

❮ Previous
Next ❯

Citations

Aug 14, 2020·The Journal of Clinical Endocrinology and Metabolism·Cui ZhangWeiqing Wang
Nov 4, 2021·JCO Oncology Practice·Paul D Ehrlichman, Namrata Vijayvergia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.